{
    "clinical_study": {
        "@rank": "13439", 
        "arm_group": {
            "arm_group_label": "Progressive Metastatic Castration-Resistant Prostate Cancer", 
            "arm_group_type": "Experimental", 
            "description": "This is a single-institution Phase 1b dose-escalation study in which eligible patients with progressive mCRPC will receive oral doses of ARN-509 in combination with everolimus."
        }, 
        "brief_summary": {
            "textblock": "The purpose of this study is to test the safety of the combination of ARN-509 plus\n      everolimus at different dose levels."
        }, 
        "brief_title": "ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate", 
        "condition": "Prostate Cancer", 
        "condition_browse": {
            "mesh_term": "Prostatic Neoplasms"
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Histologically confirmed adenocarcinoma of the prostate without neuroendocrine\n             differentiation or small cell features with progressive metastatic disease based on\n             any of the following:\n\n               -  Rise in PSA: minimum of 3 rising levels, with an interval of at least 1 week\n                  between each determination. The last determination must have a value \u2265 2 ng/mL,\n                  obtained within 4 weeks of starting study drug, or\n\n               -  Measurable disease: new or progressive soft tissue disease on CT or MRI scans,\n                  or\n\n               -  Radionuclide bone scan: at least 2 new bone lesions, as defined by the PCWG2\n                  criteria1\n\n          -  Castration-resistant prostate cancer: patients must have surgical or ongoing chemical\n             (androgen deprivation therapy) castration, with baseline testosterone level \u2264 50\n             ng/dL determined within 4 weeks of starting study drug.\n\n          -  Dose-Escalation: Prior treatment with abiraterone acetate for a minimum of 6 months.\n             At least 4 weeks must have elapsed from the last dose of abiraterone acetate.\n\n          -  Expansion Cohort only (if conducted in the study): Men with mCRPC and disease\n             progression as defined by PCWG2 within 3 months (primary resistance); or after at\n             least 6 months of treatment (acquired resistance) with abiraterone acetate. At least\n             4 weeks must have elapsed from the last dose of abiraterone.\n\n          -  Physiologic doses of corticosteroids are allowed (i.e. no more than 10 mg prednisone\n             daily).\n\n          -  Patients currently receiving bone loss prevention treatment (e.g. bisphosphonates,\n             denosumab, etc.) must be on a stable dose for at least 4 weeks prior to starting\n             study treatment.\n\n          -  Patients who received a first generation anti-androgen (e.g., bicalutamide,\n             flutamide, nilutamide) as part of their first-line hormonal therapy must have shown\n             progression of disease off the anti-androgen prior to enrollment.\n\n          -  At least 4 weeks must have elapsed from the use of androgen receptor antagonists\n             (e.g., bicalutamide, flutamide, nilutamide); 5-\u03b1 reductase inhibitors (e.g.,\n             dutasteride, finasteride, aminoglutethamide); estrogens; ketoconazole and other\n             anti-cancer pharmacologic therapy prior to enrollment.\n\n          -  At least 6 weeks must have elapsed from the use of bicalutamide if used as part of an\n             initial combined androgen blockage therapy for more than 6 months or if used as\n             second line hormonal therapy and associated with a PSA response of at least 3 months\n             duration.\n\n          -  At least 12 weeks must have elapsed from the use of Strontium-89, Radium-223 or any\n             investigational or approved immunotherapy (e.g., Provenge) prior to starting study\n             drug.\n\n          -  At least 4 weeks must have elapsed from the use of any other investigational agent\n             prior to starting study drug.\n\n          -  At least 4 weeks must have elapsed from major surgery prior to starting study drug.\n\n          -  Patients with treated, non-progressive epidural disease are eligible.\n\n          -  At least 18 years of age, with a life expectancy of at least 3 months.\n\n          -  ECOG performance status 0 or 1 (2 is allowed only if due to bone pain).\n\n          -  Toxicities related to prior therapy must either have returned to \u2264 Grade 1, baseline,\n             or deemed irreversible.\n\n          -  Physical and laboratory test findings:\n\n               -  Adequate hepatic function with serum bilirubin \u2264 1.5 times the upper\n                  institutional limits of normal (ULN), ALT and AST \u2264 2.5 x ULN. Patients with a\n                  history of Gilbert's syndrome may be enrolled if the total bilirubin is < 3\n                  mg/dL with a predominance of indirect bilirubin\n\n               -  Adequate renal function with serum creatinine \u2264 1.5 x ULN\n\n               -  Adequate hematologic function with absolute neutrophil counts \u2265 1,500 cells/mm3,\n                  platelets \u2265 100,000 cells/mm3 and hemoglobin value \u2265 9 g/dL (Note: patients\n                  whose anemia has been corrected to a hemoglobin value \u2265 9 g/dL with blood\n                  transfusions are allowed)\n\n               -  Electrolytes (including potassium, sodium, and serum calcium corrected for\n                  albumin or ionized calcium) must be within normal limits\n\n               -  Fasting serum cholesterol \u2264300 mg/dL OR \u22647.75 mmol/L AND fasting triglycerides\n                  \u22642.5x ULN. NOTE: In case one or both of these thresholds are exceeded, the\n                  patient can only be included after initiation of appropriate lipid lowering\n                  medication;\n\n               -  Adequate blood clotting time with an INR <2\n\n          -  Signed and dated informed consent document indicating that the patient (or legally\n             acceptable representative) has been informed of all pertinent aspects of the trial\n             prior to enrollment.\n\n          -  Willingness and ability to comply with scheduled visits, treatment plans, laboratory\n             tests, and other study procedures.\n\n        Exclusion Criteria:\n\n          -  Prior treatment with MDV3100, ARN-509, or PI3K/mTOR pathway inhibitors.\n\n          -  History of, or current metastases in the brain, meninges, or untreated spinal cord\n             compression.\n\n          -  Patients previously treated with chemotherapy for mCRPC. At least 12 months must have\n             elapsed from chemotherapy given in the adjuvant or neo-adjuvant setting.\n\n          -  History of any other malignancy within the previous 5 years except for the following:\n             adequately treated basal cell or squamous cell skin cancer, superficial bladder\n             cancer, stage I or II cancer currently in complete remission, or any other cancer\n             that has been in complete remission for at least 5 years.\n\n          -  History of seizure or condition that may predispose to seizure (e.g., prior stroke\n             within 1 year of starting study drug, brain arteriovenous malformation)\n\n          -  Concurrent therapy with medications known to have seizure potential\n\n          -  Known intolerance or hypersensitivity to Vitamin E, everolimus or to rapamycin\n             derivatives.\n\n          -  Use of herbal products that may decrease PSA levels (e.g., saw palmetto).\n\n          -  Known human immunodeficiency virus (HIV) infection.\n\n          -  Patients who have received live attenuated vaccines within 1 week of start of\n             Everolimus and during the study. Patient should also avoid close contact with others\n             who have received live attenuated vaccines. Examples of live attenuated vaccines\n             include intranasal influenza, measles, mumps, rubella, oral polio, BCG, yellow fever,\n             varicella and TY21a typhoid vaccines.\n\n          -  Patients with a history of non-compliance to medical regimens or who are considered\n             potentially unreliable or will not be able to complete the entire study.\n\n          -  Patients who are currently part of or have participated in any clinical investigation\n             with an investigational drug within 1 month prior to dosing.\n\n          -  Male patients whose sexual partner(s) are women of child-bearing potential (WOCBP)\n             who are not willing to use adequate contraception, during the study and for 8 weeks\n             after the end of treatment. Highly effective contraception methods include\n             combination of any two of the following (a+b or a+c or b+c):\n\n               1. Use of oral, injected or implanted hormonal methods of contraception or;\n\n               2. Placement of an intrauterine device (IUD) or intrauterine system (IUS);\n\n               3. Barrier methods of contraception: condom or occlusive cap (diaphragm or\n                  cervical/vault caps) with spermicidal foam/gel/film/cream/ vaginal suppository;\n\n               4. Total abstinence or;\n\n               5. Male/female sterilization.\n\n          -  Patients with a known impairment of gastrointestinal (GI) function or GI disease that\n             may significantly alter the absorption of oral Everolimus.\n\n          -  Patients with uncontrolled diabetes mellitus as defined by HbA1c >8% despite adequate\n             therapy. Patients with a known history of impaired fasting glucose or diabetes\n             mellitus (DM) may be included, however blood glucose and antidiabetic treatment must\n             be monitored closely throughout the trial and adjusted as necessary.\n\n          -  Patients who have any severe and/or uncontrolled medical conditions such as:\n\n             i. unstable angina pectoris, symptomatic congestive heart failure, myocardial\n             infarction \u22646 months prior to start of Everolimus, serious uncontrolled cardiac\n             arrhythmia, or any other clinically significant cardiac disease ii. Symptomatic\n             congestive heart failure of New York heart Association Class III or IV iii. active\n             (acute or chronic) or uncontrolled severe infection, liver disease such as cirrhosis,\n             decompensated liver disease, and chronic hepatitis (i.e. quantifiable HBV-DNA and/or\n             positive HbsAg, quantifiable HCV-RNA), iv. known severely impaired lung function\n             (spirometry and DLCO 50% or less of normal and O2 saturation 88% or less at rest on\n             room air), v. active, bleeding diathesis;"
            }, 
            "gender": "Male", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "58", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 3, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02106507", 
            "org_study_id": "13-025"
        }, 
        "intervention": [
            {
                "arm_group_label": "Progressive Metastatic Castration-Resistant Prostate Cancer", 
                "description": "ARN-509, 240 mg/day, oral", 
                "intervention_name": "ARN-509", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Progressive Metastatic Castration-Resistant Prostate Cancer", 
                "description": "5 mg/day of everolimus dose of everolimus will be escalated to 10 mg/day depending on the safety seen during dose escalation and steady-state trough drug levels as recommended", 
                "intervention_name": "Everolimus", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Everolimus", 
                "Sirolimus"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "keyword": [
            "ARN 509", 
            "RAD001", 
            "Everolimus", 
            "Castration-resistant", 
            "13-025"
        ], 
        "lastchanged_date": "April 3, 2014", 
        "link": {
            "description": "Memorial Sloan Kettering Cancer Center", 
            "url": "http://www.mskcc.org/"
        }, 
        "location": {
            "contact": {
                "last_name": "Dana Rathkopf, MD", 
                "phone": "646-422-4379"
            }, 
            "contact_backup": {
                "last_name": "Howard Scher, MD", 
                "phone": "646-422-4330"
            }, 
            "facility": {
                "address": {
                    "city": "New York", 
                    "country": "United States", 
                    "state": "New York", 
                    "zip": "10065"
                }, 
                "name": "Memorial Sloan Kettering Cancer Center"
            }, 
            "investigator": {
                "last_name": "Dana Rathkopf, MD", 
                "role": "Principal Investigator"
            }, 
            "status": "Recruiting"
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "Phase 1b Study of ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate", 
        "overall_contact": {
            "last_name": "Dana Rathkopf, MD", 
            "phone": "646-422-4379"
        }, 
        "overall_contact_backup": {
            "last_name": "Howard Scher, MD", 
            "phone": "646-422-4330"
        }, 
        "overall_official": {
            "affiliation": "Memorial Sloan-Kettering Cancer Center", 
            "last_name": "Dana Rathkopf, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "April 2016", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "Safety will be evaluated according to the NCI Common Terminology Criteria for Adverse Events V4.0 (CTCAE). Safety assessments will be based on medical review of adverse event reports and the results of vital sign measurements, physical examinations, and clinical laboratory tests throughout the conduct of the study.", 
                "measure": "safety", 
                "safety_issue": "Yes", 
                "time_frame": "2 years"
            }, 
            {
                "description": "Pharmacokinetic parameters (Cmax, Tmax, AUC(INF), AUC(TAU), will be derived from blood to obtain everolimus concentration or plasma to obtain ARN-509 and it's major metabolite concentration versus time data for patients in the dose escalation cohorts.", 
                "measure": "pharmacokinetics", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }, 
            {
                "description": "The first phase of the study will examine the safety of ARN-509 in combination with everolimus in patients with metastatic castration-resistant prostate cancer. Up to 2 dose levels will be tested. A standard \"3 plus 3\" dose escalation rule will be used in order to determine the MTD/RP2D. Patients will be treated in cohorts of three and the dosage will be escalated if the clinical toxicity is acceptable. The MTD is defined as the highest dose with an observed incidence of dose limiting toxicity (DLT) in no more than one out of six patients treated at a particular dose level.", 
                "measure": "maximum tolerated dose (MTD)", 
                "safety_issue": "No", 
                "time_frame": "2 years"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02106507"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "of the combination of ARN-509 plus everolimus. Matched biopsies pre- and post-treatment of metastatic sites will be collected to evaluate for downstream indicators of PI3K pathway modulation, including pS6K, p4EBP1, pAKT, AR, PHLLP 1 and 2, and additional pathways of interest. These biomarkers will be measured at baseline and after treatment to explore the association between changes in the tumor biomarkers and progression-free survival.", 
            "measure": "anti-tumor activity", 
            "safety_issue": "No", 
            "time_frame": "2 years"
        }, 
        "source": "Memorial Sloan-Kettering Cancer Center", 
        "sponsors": {
            "collaborator": {
                "agency": "Aragon Pharmaceuticals, Inc.", 
                "agency_class": "Industry"
            }, 
            "lead_sponsor": {
                "agency": "Memorial Sloan-Kettering Cancer Center", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "April 2014", 
        "study_design": "Endpoint Classification: Safety Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "April 2014"
    }
}